2018). Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia and frontotemporal dementia. Neurobiology of Aging. Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia and frontotemporal dementia, Neurobiology of Aging (2018), Abstract Analysis of 226 exome-sequenced UK cases of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) identified two individuals that harboured a P497H and P506S UBQLN2 mutation respectively (n=0.9%). The P506S index case presented with behavioral variant frontotemporal dementia (FTD) at the age of 54, then progressed to ALS surviving three years. Three sons presented with a) slowly progressive pure spastic paraplegia with an onset at 25 years and b) ALS with disease onset of 25yrs and survival of two years respectively and c) ALS presenting symptoms at 26yrs of age. Analysis of post mortem tissue from the index case revealed frequent neuronal cytoplasmic UBQLN2 positive inclusions in the dentate gyrus and TDP-43 positive neuronal cytoplasmic inclusions in the frontal and temporal cortex and granular cell layer of the dentate gyrus of the hippocampus. The presentation of multiple intrafamilial phenotypes suggests P506S to be pleiotropic. Furthermore, a comprehensive analysis of published UBQLN2 mutations demonstrated that only proline-rich domain mutations contribute to a significantly earlier age of onset in male patients (p=0.0026).
. Mutations in UBQLN2 were originally identified in X-linked kindreds with ALS and FTD accounting for a modest proportion of FALS cases (2.7% in Deng et al., 2011) . A recent large-scale burden analysis of exome sequencing data has independently verified the significance of UBQLN2 mutations in FALS (Kenna et al., 2016) . Interestingly, UBQLN2 mutations are associated with a wide range of neurodegenerative phenotypes (ALS+/-FTD, FTD, Primary Lateral Sclerosis (PLS) and Hereditary Spastic Paraplegia (HSP)), (Vengoechea et al., 2013) . Here we present further evidence of this phenomenon by the presentation of striking intrafamilial phenotypic variation in a family carrying a p.P506S UBQLN2 mutation supported by patient specific neuropathology demonstrating UBQLN2 positive aggregates.
Methods

Participants
The DNA of 226 FALS patients was exome sequenced as part of an existing novel ALS gene hunting project. All cases were from the UK, and sourced from local ALS clinics and the MNDA DNA Bank. All patients were diagnosed with ALS according to El Escorial criteria (Brooks et al., 2000) and full consent was obtained for research purposes. All cases were devoid of mutations in TARDBP, SOD1, FUS, OPTN, VCP, TBK1, MATR3, PFN1, TUBA4A, ANXA11, CHCHD10, NEK1, CCNF, C21ORF2, KIF5A, and the C9ORF72 intronic GGGGCC expansion.
DNA from 500 UK SALS cases were screened by Sanger sequencing for mutations in the proline rich encoding region (residues 491 to 526) of UBQLN2 (NM_013444), which is a mutation hotspot.
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Immunohistochemistry
In brief, sections of 7µm thickness were cut from paraffin-embedded tissue blocks, then deparaffinised in xylene. Endogenous peroxidases were blocked by immersion in 2.5% H 2 O 2 in methanol and immunohistochemistry performed. To enhance antigen retrieval sections were kept in citrate buffer (pH 6) for 10 minutes following microwave treatment. After blocking in normal rabbit serum (1:10, DAKO, UK) in Tris-buffered saline (pH 7.6), anti-Ubiquilin2 antibody
(1:500, Abnova) was applied overnight at 4 o C. Following washes, sections were incubated with biotinylated secondary antibody (rabbit anti-mouse, 1:100, DAKO, UK), followed by avidin:biotinylated enzyme complex (Vectastain Elite ABC kit, Vector Laboratories, Peterborough, UK). Finally sections were incubated for 10-15 min with 0.5 mg/mL 3,3′diaminobenzidine chromogen (Sigma-Aldrich Company Ltd, Dorset, UK) in TBS containing 0.05% H 2 O 2 . Sections were counterstained with Harris' haematoxylin and immunostaining was analysed using a light microscope (Leica, Wetzlar, Germany).
Statistics
The significance between the means for the ages of females and males carrying UBQLN2 mutations in this and published studies were calculated using a two-tailed t-test with the Graphpad online calculator (https://www.graphpad.com/quickcalcs/ttest1/).
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Results
We performed exome sequencing in 226 FALS and identified two UBQLN2 mutations; P497H and P506S in two FALS (0.88% frequency), both located in the proline rich region and previously described , Vengoechea et al. 2013 , Deng et. al., 2011 , Teyssou et.al 2017 (Fig 1A, 1B ). Both mutations were absent from 1000 local UK controls and online exome control databases (1000 Genomes, Exome Variant Server n=6503 and ExAC n=60,706).
The male index patient harbouring the P497H mutation presented at 39 years of age with symptoms in the fingers of the right hand, slowly progressing to involve both arms, which demonstrated fasciculations and profound wasting. There were no bulbar features. He died 8 years after disease onset with no evidence of FTD ( Fig 1A, 1C and 1D ).
Post mortem tissue was available from the P506S ALS/FTD proband ( Fig 1B, II:2) . Staining with a UBQLN2 antibody showed frequent neuronal cytoplasmic UBQLN2 positive inclusions M A N U S C R I P T
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in the dentate gyrus (Fig 2A) and scattered neuronal cytoplasmic inclusions and neurites in the neocortex. Unfortunately, spinal cord tissue was not available to confirm presence of motor neurone damage. Thirteen cases of ALS, FTLD-ALS, and FTLD-TDP devoid of known ALS/FTD mutations were also stained with the UBQLN2 antibody. The density and distribution of the staining was markedly variable (data not shown), as has been described previously (Brettschneider et al 2012) . Some cases had more, and some less extensive staining than the P506S ALS/FTD proband ( Fig 2B) . No UBQLN2 inclusions were seen in the cerebral tissue from the control cases ( Fig 2C) . Histological examination of the P506S proband also showed frequent TDP-43 positive neuronal cytoplasmic inclusions (NCIs) in the frontal and temporal cortices and granular cell layer of the dentate gyrus of the hippocampus (Fig 2D-E) . TDP-43 positive neuronal cytoplasmic inclusions were also observed in the XIIth cranial nerve nucleus ( Fig 2F) . Deposition of TDP-43 was also noticed in the putamen, thalamus and amygdala. The motor cortex revealed only occasional TDP-43 positive NCIs. This case of TDP-43 pathology is classified as most closely matching histological type B as there were frequent granular intraneuronal cytoplasmic TDP-43 inclusions but only occasional neurites, which are frequently observed in cases of FTD and ALS.
As two mutations were identified in the proline rich domain, we investigated this hotspot further by Sanger Sequencing this domain in 500 UK SALS cases. However, no mutations were detected. Interestingly, the male UBQLN2 carriers from our P497H and P506S kindreds (Fig 2A   and B) had a significantly earlier age of onset compared to females (females=54,69, males=25,26,39,40 t=3.8069, p=0.0190). This suggests that due to the lack of a wild-type allele (UBQLN2 is located on the X chromosome), male UBQLN2 mutation carriers may have elevated disease penetrance and therefore manifest ALS earlier than female heterozygous UBQLN2 mutations carriers. This has been previously observed in several UBQLN2 screening studies (Deng et al., 2011; Vengoechea et al., 2013 , Teyssou et.al 2017 . With these observations, we therefore surveyed all published ALS+/-FTD cases harbouring UBQLN2 mutations to address this question. Supplementary Table 1 lists all index cases with UBQLN2 mutations in ALS+/-FTD cases published to date. Ten of the 28 different amino acid changes observed reside in the PXX domain and most of the index cases are Caucasian. 56% (24/43) of the cases were female and demonstrated a significantly later age of onset than males (females: mean = 51.75 years, males: mean = 38.5 years, t = 2.6110, p = 0.0126). In particular, when cases harbouring proline M A N U S C R I P T
rich domain mutations were analysed in isolation, the age of onset between the two genders was more pronounced and significantly reduced in males (females: mean = 53.56 years, males: mean = 34.38 years, t = 3.6053, p = 0.0026). Interestingly, within the proline rich domain, with the exception of variants P509S and P525S that are heterozygous in ExAC in approximately 1:10,000 and 1:1,000 Europeans respectively, all other ALS linked proline rich domain variants are novel. Moreover, in gnomAD, while P509S is again found 1:10,000 Europeans, the P525S variant is frequently present in Ashkenazi Jews, with around 1% of the population carrying the common variant.
Discussion
We have identified two UBQLN2 mutations, P497H and P506S that are absent from ExAC and local UK controls in a cohort of 226 ALS patients (0.88% frequency). Although previously identified, this report confirms that both variants are common, recurrent UBQLN2 mutations that occur in ALS patients from distinct populations, emphasizing the requirement for routine diagnostic screening (Deng et al., 2011; Vengoechea et al., 2013; Gellera et al., 2013; Özoğuz et al., 2015) . Significantly though, we demonstrate here that the P506S mutation results in UBQLN2 positive aggregates in post-mortem tissue. This is the first neuropathological report of a patient harbouring a UBQLN2 P506S mutation that adds to the characterized list of proline rich mutations in ALS/FTD tissue (Deng et al., 2011; Williams et al., 2012; Scotter et al., 2016) .
Furthermore, this provides additional evidence of aggregation prone mutations located in the proline rich domain of Ubiquilin 2; highlighting the significance of this region. Furthermore, we observed striking intra-familial clinical phenotypic heterogeneity of individuals possessing the P506S mutation. Firstly the proband P506S mother presenting initially with FTD and then subsequently with ALS, then her two sons demonstrating rapidly progressive, young onset ALS in contrast to another son with early onset HSP. This intra-familial phenotypic difference due to P506S has previously been reported (Vengoechea et al., 2013 , Teyssou et.al 2017 . Interestingly, the P506 residue in particular when mutated, is highly prone to manifesting multiple phenotypes as Teyssou et.al also reported a P506A carrying kindred with a predominant upper motor neuron phenotype that progressed, in time, to ALS. In light of this observed reduction in age of onset, a comprehensive analysis of published data, suggests that the proline-rich domain UBQLN2 M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT mutations in particular account for the significant earlier disease onset in males. However, why male carriers with the same P506S mutation would present with either ALS or HSP is currently unexplainable. One possibility is that UBQLN2 may be variably expressed in different sets of neurons, or potentially X chromosome inactivation due to somatic mosaicism may skew or influence either penetrance or neurodegenerative phenotype as previously postulated (Vengoechea et al., 2013 , Teyssou et.al 2017 . This is fuel for further investigation in UBQLN2 mediated ALS/FTD. However, our study highlights the importance of proline-rich domain UBQLN2 mutations firstly as a rare contributor to ALS pathology and also to neurodegenerative neuronal cytoplasmic inclusions positive for Ubiquilin 2 in the cerebral cortex and here in the dentate gyrus of the proband (A) whilst neuronal cytoplasmic inclusions positive for Ubiquilin 2 were found in cases of sporadic FTLD-TDP, FTLD-ALS and here in an SALS case (B). No staining for Ubiquilin 2 was found in the dentate gyrus of control cases (C). Also, staining for pTDP-43 revealed neuronal cytoplasmic inclusions positive for pTDP-43 in the granular cell layer of dentate gyrus of hippocampus and upper layers of the frontal and temporal cortex of the proband (D-E). pTDP-43 positive neuronal cytoplasmic inclusions were also observed in the XIIth nerve nucleus (F). Scale bar (A-E)-20µm, F-30 µm. • We identified 2 patients, each carrying a different mutation in the UBQLN2 gene; P497H and P506S.
Supplementary
• The P506S mutation segregated with disease in a family with behavioural variant FTD, spastic paraplegia and ALS.
• Analysis of post mortem tissue from the index case revealed frequent neuronal UBQLN2 positive cytoplasmic inclusions in the dentate gyrus and TDP-43 positive neuronal cytoplasmic inclusions in the frontal and temporal cortex and granular cell layer of the dentate gyrus of the hippocampus.
• Significantly earlier age of onset was observed in male patients with mutations in the proline rich region of UBQLN2 after performing a comprehensive analysis of all published UBQLN2 mutations to date.
